1,451 results on '"Stamatoullas A"'
Search Results
2. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
3. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
4. Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study
5. Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study
6. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
7. High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock
8. PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
9. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.
10. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
11. Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials.
12. Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
13. Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
14. Successful treatment of severe post hematopoietic stem cell transplantation bronchiolitis obliterans syndrome with lung transplantation in a patient with multi‐organ chronic graft‐versus‐host disease
15. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
16. Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
17. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
18. Valeur pronostique de paramètres de massivité mesurés sur la TEP/TDM 18F-FDG pré-thérapeutique dans le lymphome de Hodgkin de stade avancé
19. Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma
20. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
21. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas
22. Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
23. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
24. Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study
25. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
26. Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
27. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network
28. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial
29. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
30. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH)
31. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study
32. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
33. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
34. Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
35. Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy
36. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
37. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: a case report
38. Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study
39. Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials
40. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH):A Multicenter, Open-Label, Randomized, Phase II Trial
41. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
42. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
43. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
44. Red blood cell transfusion burden in myelodysplastic syndromes ( <scp>MDS</scp> ) with ring Sideroblasts ( <scp>RS</scp> ): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies ( <scp>GFM</scp> )
45. A randomised phase <scp>II</scp> study of azacitidine ( <scp>AZA</scp> ) alone or with Lenalidomide ( <scp>LEN</scp> ), Valproic acid ( <scp>VPA</scp> ) or Idarubicin ( <scp>IDA</scp> ) in <scp>higher‐Risk MDS</scp> or low blast <scp>AML</scp> : <scp>GFM</scp> 's 'pick a winner' trial, with the impact of somatic mutations
46. Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
47. Azacitidine for the treatment of relapsed and refractory AML in older patients
48. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study
49. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
50. Work and education interruption in long-term Hodgkin lymphoma survivors : an analysis among patients from nine EORTC-LYSA trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.